AIMS AND METHODS: To evaluate the clinical value of (18) F-fluorodihydroxyphenylalanine ((18) F-FDOPA) PET in relation to tumour localization and the patient's genetic status in a large series of pheochromocytoma/paraganglioma (PHEO/PGL) patients and to discuss in detail false-negative results. A retrospective study of PGL patients who were investigated with (18) F-FDOPA PET or PET/CT imaging in two academic endocrine tumour centres was conducted (La Timone University Hospital, Marseilles, France and National Institutes of Health (NIH), Bethesda, MD, USA). RESULTS: One hundred sixteen patients (39·7% harbouring germline mutations in known disease susceptibility genes) were evaluated for a total of 195 PHEO/PGL foci. (18) F-FDOPA PET correctly detected 179 lesions (91·8%) in 107 patients (92·2%). Lesion-based sensitivities for parasympathetic PGLs (head, neck, or anterior/middle thoracic ones), PHEOs, and extra-adrenal sympathetic (abdominal or posterior thoracic) PGLs were 98·2% [96·5% for Timone and 100% for NIH], 93·9% [93·8 and 93·9%] and 70·3% [47·1 and 90%] respectively (P < 0·001). Sympathetic (adrenal and extra-adrenal) SDHx-related PGLs were at a higher risk for negative (18) F-FDOPA PET than non-SDHx-related PGLs (14/24 vs 0/62, respectively, P < 0·001). In contrast, the risk of negative (18) F-FDOPA PET was lower for parasympathetic PGLs regardless of the genetic background (1/90 in SDHx vs 1/19 in non-SDHx tumours, P = 0·32). (18) F-FDOPA PET failed to detect two head and neck PGLs (HNPGL), likely due to their small size, whereas most missed sympathetic PGL were larger and may have exhibited a specific (18) F-FDOPA-negative imaging phenotype. (18) F-FDG PET detected all the missed sympathetic lesions. CONCLUSIONS: (18) F-FDOPA PET appears to be a very sensitive functional imaging tool for HNPGL regardless of the genetic status of the tumours. Patients with false-negative tumours on (18) F-FDOPA PET should be tested for SDHx mutations.
AIMS AND METHODS: To evaluate the clinical value of (18) F-fluorodihydroxyphenylalanine ((18) F-FDOPA) PET in relation to tumour localization and the patient's genetic status in a large series of pheochromocytoma/paraganglioma (PHEO/PGL) patients and to discuss in detail false-negative results. A retrospective study of PGL patients who were investigated with (18) F-FDOPA PET or PET/CT imaging in two academic endocrine tumour centres was conducted (La Timone University Hospital, Marseilles, France and National Institutes of Health (NIH), Bethesda, MD, USA). RESULTS: One hundred sixteen patients (39·7% harbouring germline mutations in known disease susceptibility genes) were evaluated for a total of 195 PHEO/PGL foci. (18) F-FDOPA PET correctly detected 179 lesions (91·8%) in 107 patients (92·2%). Lesion-based sensitivities for parasympathetic PGLs (head, neck, or anterior/middle thoracic ones), PHEOs, and extra-adrenal sympathetic (abdominal or posterior thoracic) PGLs were 98·2% [96·5% for Timone and 100% for NIH], 93·9% [93·8 and 93·9%] and 70·3% [47·1 and 90%] respectively (P < 0·001). Sympathetic (adrenal and extra-adrenal) SDHx-related PGLs were at a higher risk for negative (18) F-FDOPA PET than non-SDHx-related PGLs (14/24 vs 0/62, respectively, P < 0·001). In contrast, the risk of negative (18) F-FDOPA PET was lower for parasympathetic PGLs regardless of the genetic background (1/90 in SDHx vs 1/19 in non-SDHx tumours, P = 0·32). (18) F-FDOPA PET failed to detect two head and neck PGLs (HNPGL), likely due to their small size, whereas most missed sympathetic PGL were larger and may have exhibited a specific (18) F-FDOPA-negative imaging phenotype. (18) F-FDG PET detected all the missed sympathetic lesions. CONCLUSIONS: (18) F-FDOPA PET appears to be a very sensitive functional imaging tool for HNPGL regardless of the genetic status of the tumours. Patients with false-negative tumours on (18) F-FDOPA PET should be tested for SDHx mutations.
Authors: Henri J L M Timmers; Mohiuddin Hadi; Jorge A Carrasquillo; Clara C Chen; Lucia Martiniova; Millie Whatley; Alexander Ling; Graeme Eisenhofer; Karen T Adams; Karel Pacak Journal: J Nucl Med Date: 2007-09-14 Impact factor: 10.057
Authors: Helle-Brit Fiebrich; Adrienne H Brouwers; Michiel N Kerstens; Milan E J Pijl; Ido P Kema; Johan R de Jong; Pieter L Jager; Philip H Elsinga; Rudi A J O Dierckx; Jacqueline E van der Wal; Wim J Sluiter; Elisabeth G E de Vries; Thera P Links Journal: J Clin Endocrinol Metab Date: 2009-07-21 Impact factor: 5.958
Authors: David Taïeb; Henri J Timmers; Elif Hindié; Benjamin A Guillet; Hartmut P Neumann; Martin K Walz; Giuseppe Opocher; Wouter W de Herder; Carsten C Boedeker; Ronald R de Krijger; Arturo Chiti; Adil Al-Nahhas; Karel Pacak; Domenico Rubello Journal: Eur J Nucl Med Mol Imaging Date: 2012-08-28 Impact factor: 9.236
Authors: Henri J L M Timmers; Anna Kozupa; Clara C Chen; Jorge A Carrasquillo; Alexander Ling; Graeme Eisenhofer; Karen T Adams; Daniel Solis; Jacques W M Lenders; Karel Pacak Journal: J Clin Oncol Date: 2007-06-01 Impact factor: 44.544
Authors: D Taïeb; L Tessonnier; F Sebag; P Niccoli-Sire; I Morange; C Colavolpe; C De Micco; A Barlier; F F Palazzo; J F Henry; O Mundler Journal: Clin Endocrinol (Oxf) Date: 2008-04-03 Impact factor: 3.478
Authors: David Taïeb; Alexandre Kaliski; Carsten C Boedeker; Victoria Martucci; Tito Fojo; John R Adler; Karel Pacak Journal: Endocr Rev Date: 2014-07-17 Impact factor: 19.871
Authors: Elise M Blanchet; David Taieb; Corina Millo; Victoria Martucci; Clara C Chen; Maria Merino; Peter Herscovitch; Karel Pacak Journal: J Nucl Med Date: 2015-09-10 Impact factor: 10.057
Authors: Elise M Blanchet; Corina Millo; Victoria Martucci; Roberto Maass-Moreno; David A Bluemke; Karel Pacak Journal: Clin Nucl Med Date: 2014-03 Impact factor: 7.794
Authors: Chloé C Feral; Floriane S Tissot; Lionel Tosello; Nicolas Fakhry; Fréderic Sebag; Karel Pacak; David Taïeb Journal: Eur J Nucl Med Mol Imaging Date: 2016-11-29 Impact factor: 9.236
Authors: Karel Pacak; David Taïeb; Elise M Blanchet; Sophie Gabriel; Victoria Martucci; Nicolas Fakhry; Clara C Chen; Arnaud Deveze; Corina Millo; Anne Barlier; Morgane Pertuit; Anderson Loundou Journal: Eur J Clin Invest Date: 2014 Impact factor: 4.686